Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2026	Sep. 30, 2025
Operating activities
Net loss	$ (211,972)	$ (255,418)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation and amortization	46,257	29,388
Amortization of acquired intangible assets	17,100	0
Amortization of premiums and accretion of purchase discounts on investment securities	0	32
Non-cash settlement expense	1,226	0
Non-cash lease expense	20,417	14,751
Stock-based compensation	304,309	261,822
Change in fair value of warrants and preferred stock of related party equity investment	(166)	(3,235)
Revaluation of contingent consideration	8,220	0
Other non-cash items	263	29
Non-cash expense recovery	(2,023)	(1,084)
Changes in operating assets and liabilities:
Accounts receivable	(174,826)	27,786
Inventory	(23,261)	(19,900)
Operating lease right-of-use assets	1,368	88
Prepaid expenses and other assets	(5,128)	(8,982)
Accounts payable	76,016	12,346
Accrued compensation	66,819	48,200
Operating lease liabilities	(18,311)	(14,245)
Other accrued liabilities and other liabilities	22,156	48,197
Deferred revenue	10,408	1,638
Net cash provided by operating activities	138,895	141,413
Investing activities
Proceeds from maturity of investments	0	22,000
Purchases of property and equipment, net	(124,245)	(70,117)
Purchase of intangible assets, net	0	(12,500)
Cash paid for business combination, net	(243)	0
Investment in related party	(10,000)	0
Net cash used in investing activities	(134,488)	(60,617)
Financing activities
Proceeds from exercise of stock options	5,736	2,819
Cash paid to satisfy statutory withholding requirement for net settlement of cashless stock option exercises	(5,413)	0
Proceeds from the issuance of common stock under the employee stock purchase plan	16,430	12,236
Stock issuance costs	(105)	0
Net cash provided by financing activities	16,648	15,055
Net change in cash, cash equivalents and restricted cash	21,055	95,851
Cash, cash equivalents and restricted cash, beginning of period	1,076,140	945,587
Cash, cash equivalents and restricted cash, end of period	1,097,195	1,041,438
Supplemental disclosure of cash flow information:
Cash paid for interest	2,685	3,078
Non-cash investing and financing activities:
Purchases of property and equipment in accounts payable and accruals	26,860	(1,789)
Acquisition of warrants	7,162	0
Amounts accrued for acquisition of intangible assets	0	17,500
Consideration for business combination	30	0
Issuance of common stock for intangible assets	774	0
Issuance of common stock for bonuses	47,026	32,875
Stock-based compensation included in capitalized software development costs	1,847	2,275
Foresight Diagnostics, Inc.
Adjustments to reconcile net loss to net cash provided by operating activities:
Amortization of acquired intangible assets	17,123	$ 0
Revaluation of contingent consideration	$ 10,700